BidaskClub downgraded shares of Allergan PLC. (NYSE:AGN) from a sell rating to a strong sell rating in a report published on Friday.

Several other research firms also recently weighed in on AGN. Deutsche Bank AG reiterated a buy rating and set a $273.00 target price (up from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Goldman Sachs Group, Inc. (The) downgraded Allergan PLC. from a buy rating to a neutral rating and set a $262.00 target price on the stock. in a research report on Wednesday, May 10th. Royal Bank Of Canada increased their target price on Allergan PLC. from $279.00 to $284.00 and gave the stock an outperform rating in a research report on Wednesday, May 10th. Wells Fargo & Company reiterated an outperform rating and set a $280.00 target price (up from $270.00) on shares of Allergan PLC. in a research report on Wednesday, August 9th. Finally, Credit Suisse Group set a $288.00 target price on Allergan PLC. and gave the stock a buy rating in a research report on Saturday, August 5th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company. Allergan PLC. presently has an average rating of Buy and a consensus price target of $275.49.

Shares of Allergan PLC. (NYSE:AGN) opened at 223.94 on Friday. The stock has a market cap of $74.86 billion, a P/E ratio of 6.82 and a beta of 1.16. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The company’s 50-day moving average is $240.49 and its 200-day moving average is $238.48.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the prior year, the business posted $3.35 earnings per share. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. Equities analysts expect that Allergan PLC. will post $16.27 EPS for the current fiscal year.

WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/29/bidaskclub-downgrades-allergan-plc-agn-to-strong-sell.html.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.25%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

Large investors have recently modified their holdings of the stock. Hudock Capital Group LLC raised its stake in shares of Allergan PLC. by 0.4% in the second quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock worth $138,000 after buying an additional 2 shares during the period. GWM Advisors LLC raised its stake in shares of Allergan PLC. by 0.4% in the first quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock worth $300,000 after buying an additional 5 shares during the period. Burns J W & Co. Inc. NY raised its stake in shares of Allergan PLC. by 0.7% in the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after buying an additional 6 shares during the period. Pacific Center for Financial Services raised its stake in shares of Allergan PLC. by 1.3% in the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after buying an additional 7 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC raised its stake in shares of Allergan PLC. by 0.5% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock worth $405,000 after buying an additional 9 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.